Trial Profile
A phase IIb/III trial of MLN 591RL [177Lu-J591] in patients with castrate-resistant prostate cancer.
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 07 Jul 2017
Price :
$35
*
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors ATLAB Pharma; BZL Biologics; Telix Pharmaceuticals
- 02 Nov 2011 New trial record